News & Updates
Showing Oncology articles
Showing
Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer
In the PREcoopERA window-of-opportunity trial, the selective estrogen receptor degrader (SERD) giredestrant shows robust anticancer activity, either alone or in combination with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin, in premenopausal women with ER+/HER2– operable invasive breast cancer.
Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer
18 May 2026
First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC
Combination treatment with capivasertib and paclitaxel falls short of prolonging overall survival (OS) compared with placebo plus paclitaxel in patients with metastatic triple-negative breast cancer (TNBC), either in the overall or PIK3CA/AKT1/PTEN-altered populations, as shown in the CAPItello-290 trial
First-line capivasertib-paclitaxel therapy misses survival target in metastatic TNBC
12 May 2026
Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?
Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.
Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?
12 May 2026
CtDNA testing predicts recurrence, enables personalized management in MIBC
Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.